DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

Understanding dementia and Alzheimer’s disease is essential for maintaining a proactive approach to our well-being.

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

Dear ProMIS Shareholders, In my first year as the Chief Executive Officer of ProMIS, we made great strides advancing our mission-driven innovation focused on developing precision-targeted therapies ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

The sleep aid Ambien could be allowing toxic proteins to pollute the brain, potentially increasing a person’s risk of ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...